Rise and shine, everyone. The middle of the week is upon us. While this may imply an extraordinarily challenging day lies ahead, we are invigorated by the presence of a bright sun overhead and a steaming cup of stimulation in hand. How else to cope? Feel free to join us, of course. Now, though, the time has come to get on with it. So here is your menu of tidbits. Hope your day is smashing and do let us know if you run across something interesting. Cheers...
Number Of US Deaths From Alzheimer's Is Growing (Reuters)
Valent Pays $348M For Obagi Skin Care Company (Globe & Mail)
Biogen MS Pill Gets Eights More Years Of Patent Protection (Bloomberg News)
German Cost Regulator Rejects Bayer And Regeneron Eye Drug (PM Live)
FDA Reviewers Says Opioid Drug Dose May Be Insufficient (Reuters)
Almirall May Pull Cannabis Drug From Germany Over Price Row (Reuters)
Savient Pharma Shares Sink On Gout Drug Sales (Associated Press)
Connecticut Advances Bill To Promote Biopharma Industry (The Day)
FDA Rejects Pharmaxis Cystic Fibrosis Drug (Pharma Times)
Novo Nordisk Insulin Passes Early-Stage Study (Bloomberg News)
Merck Serono And Bristol-Myers Sign Diabetes Pact For China (PM Live)
Supreme Court To Consider Former J&J Rep's Frozen Funds (Dow Jones)
Roche Joins Bidding For Life Tech (Reuters)
EDITOR'S NOTE: Please check this post for additional items during the day






9 Comments
Thanks for asking about that. As you know, the Pharmalittle column aggregates stories and, yes, headlines are imperfect. This was a Reuters item, which was headlined similarly. And this is how the story began...
"Titan Pharmaceuticals Inc's experimental drug to treat opioid addiction was shown to be more effective than placebo in a clinical trial, but patients' response suggested that the proposed dosage might be too low, reviewers for the U.S. Food and Drug Administration said in documents published on Tuesday."
Assuming the story is correct - again, this is an aggregated item and I did not spend time doing my own reporting - the headline would appear to be appropriate. If there is evidence otherwise, it can be changed, of course.
Regards ed
Because nobody would care if the headline was "Costs for care in the last years of Alzheimers are exploding"?
I hate when politics try to do science. Ends usually in very expensive nonsense.
Of course now the children are pissed off cause Big Mama is still alive and they have to keep shelling out $100K a year to keep her going in the nursing home cause the doctor won't give her "50 at 5", even though she's completely demented piss poor protoplasm and scores zero on the minimental status exam.